[go: up one dir, main page]

SG11201809976PA - Protection of plant extracts and compounds from degradation - Google Patents

Protection of plant extracts and compounds from degradation

Info

Publication number
SG11201809976PA
SG11201809976PA SG11201809976PA SG11201809976PA SG11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA SG 11201809976P A SG11201809976P A SG 11201809976PA
Authority
SG
Singapore
Prior art keywords
international
cannabinoids
pct
degradation
street
Prior art date
Application number
SG11201809976PA
Other languages
English (en)
Inventor
Luis Vitetta
Sean Hall
Original Assignee
Medlab Ip Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901758A external-priority patent/AU2016901758A0/en
Application filed by Medlab Ip Pty Ltd filed Critical Medlab Ip Pty Ltd
Publication of SG11201809976PA publication Critical patent/SG11201809976PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201809976PA 2016-05-11 2017-05-11 Protection of plant extracts and compounds from degradation SG11201809976PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901758A AU2016901758A0 (en) 2016-05-11 Protection of plant extracts and compounds from degradation
PCT/AU2017/050430 WO2017193169A1 (fr) 2016-05-11 2017-05-11 Protection d'extraits végétaux et de composés contre la dégradation

Publications (1)

Publication Number Publication Date
SG11201809976PA true SG11201809976PA (en) 2018-12-28

Family

ID=60266066

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809976PA SG11201809976PA (en) 2016-05-11 2017-05-11 Protection of plant extracts and compounds from degradation

Country Status (6)

Country Link
US (2) US20190315704A1 (fr)
EP (1) EP3454849A4 (fr)
AU (1) AU2017261847B2 (fr)
CA (1) CA3023767A1 (fr)
SG (1) SG11201809976PA (fr)
WO (1) WO2017193169A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (fr) 2018-01-31 2020-12-09 Canopy Holdings, Llc Poudre de chanvre
US20210315817A1 (en) * 2018-08-20 2021-10-14 Hexo Operations Inc. Cannabinoid based self-emulsion systems for infused compositions
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
CN110038251B (zh) * 2019-05-30 2021-07-30 汉义生物科技(北京)有限公司 一种降解大麻素的方法
EP4010024A4 (fr) * 2019-08-08 2023-05-03 Neptune Wellness Solutions Inc. Préparations de cannabis pour la voie orale et leurs procédés de fabrication
WO2022232574A1 (fr) 2021-04-29 2022-11-03 Tilray, Inc. Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procédés de fabrication et leurs utilisations
IT202100014909A1 (it) * 2021-06-08 2022-12-08 Velleja Res S R L Formulazioni oleose di cannabinoidi
US20230036051A1 (en) * 2021-07-21 2023-02-02 Resurgent Biosciences, Inc. Cannabinoid storage stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032962A2 (fr) * 2005-09-09 2007-03-22 University Of Kentucky Compositions et procédés destinés à une administration intranasale de cannabidoïdes tricycliques
AU2007281918A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
WO2009020666A1 (fr) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Formulations liquides à usage oral de cannabinoïdes et procédés de traitement avec celles-ci
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法

Also Published As

Publication number Publication date
AU2017261847B2 (en) 2023-03-30
WO2017193169A1 (fr) 2017-11-16
CA3023767A1 (fr) 2017-11-16
EP3454849A4 (fr) 2019-11-27
AU2017261847A1 (en) 2018-12-13
US20220274943A1 (en) 2022-09-01
EP3454849A1 (fr) 2019-03-20
US20190315704A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
SG11201809976PA (en) Protection of plant extracts and compounds from degradation
SG11201906795SA (en) Novel plant cells, plants, and seeds
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201907034PA (en) Methods of treating influenza
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201804729RA (en) Methods and compositions for treating a serpinc1-associated disorder
SG11201408054RA (en) Pegylated oxm variants
SG11201804368QA (en) Storage assembly for prosthetic valve
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201810192TA (en) Antibacterial compositions
SG11201811579VA (en) Chemiluminescent substrates
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201900665VA (en) Cannabis composition
SG11201407200TA (en) Liquid formulation
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201903427UA (en) Deodorizing agent comprising zinc neodecanoate
SG11201809537VA (en) Urea motif containing compounds and derivatives thereof as antibacterial drugs
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201810516UA (en) Combinations comprising histone deacetylase inhibitors
SG11201811093RA (en) Antimicrobial compounds and methods for use thereof
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201807404XA (en) Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
SG11201805423TA (en) Indolinones compounds and their use in the treatment of fibrotic diseases
SG11201408509PA (en) Racecadotril lipid compositions